ASCO 2020：11项中国科学研究入选口头报告，17项Poster报告

受全球最初冠禽流感影响，原计划于5年末29日~6年末2日在纽约举行的最初泽西州诊疗研习（ASCO）年会上周将首次以线上形式承办，这是目前最大规模的线上盛会。今天，全会的简述题目公布，共103个sessions，当中华人民共和国共11项数据分析入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

磺酸替尼或拉帕替尼加卡培他浜可用HER2+心肌梗死乳腺胰脏（PHOEBE）：一项III期随机测试。

音乐会：心肌梗死乳腺胰脏

原作者：当中华人民共和国医学科学院病房徐兵河研究员、马飞研究员，南京大学附属机构病房胡夕春研究员等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴持续性乳腺胰脏标准疗程后卡培他浜维持节拍化学治疗的III期测试（SYSUCC-001）。

音乐会：乳腺胰脏—均匀分布/区域/基本功能疗程

原作者：当北京大学预防当中心地带称王树森研究员等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用心肌梗死脑的表现型相似持续性来预期脑脊液当中反向DNA检测的概率: 最初工具箱对抗外公输掉

音乐会：最初工具箱应对外公疑问

原作者：刘美芹 刘昔等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

人口为120人非尼对毛里塔尼亚拉非尼作为后半期食道细胞会胰脏的三线疗程：一项解禁字句、随机、多当中心地带II/III期测试。

音乐会：消化系统胰脏—食道输尿管、肝脏和食道胆

原作者：南京大学伊万基夫齐病房毕锋研究员、当中华人民共和国人民解放军南开病房秦叔逵研究员等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

当中华人民共和国后半期食道胰脏症状阿帕替尼二线疗程：一项随机、安慰剂相符合、CPAIII期数据分析

音乐会：消化系统胰脏—食道输尿管、肝脏和食道胆

原作者：当中华人民共和国人民解放军南开病房秦叔逵研究员、南京大学伊万基夫齐病房刘秋研究员等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期风湿热卵巢胰脏二次细胞会减灭术的一项随机III期测试：SOC1 / SGOG-OV2。

栏目：妇科乳癌

原作者：南京大学附属机构当永康病房臧荣余研究员等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治持续性乳腺切除术后基本功能疗程当中的序贯放化学治疗对比单独放疗或同步放化学治疗（STARS数据分析）：一项随机、相符合、解禁字句的III期测试。

全会：妇科乳癌

原作者：当北京大学预防当中心地带黄鹤研究员、刘继红研究员等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比化学治疗可用可切除的EGFR基因型的N1-N2期NSCLC-随机III期诊疗测试的最终某种程度存活数据分析。

栏目：肺胰脏—非小细胞会均匀分布-区域/小细胞会/其他胸部

原作者：江门市人民病房吴一龙研究员等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因型寡移到非小细胞会肺胰脏症状三线赖氨酸还原酶抑制剂牵头或不牵头尽力机动部队均匀分布放疗：III期解禁字句诊疗随机测试（SINDAS）的当后半期结果（NCT02893332）。

栏目：肺胰脏-非小细胞会移到

原作者：南充人民病房曾铭研究员等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对更进一步死亡者-1（PD-1）的人源化IgG4单克隆抗体牵头阿昔替尼可用心肌梗死黏膜脑瘤症状的Ib期数据分析的总存活期和生命体标志物数据分析。

栏目：脑瘤/皮肤胰脏

原作者：南京大学病房郭军、盛锡楠研究员等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用持续性和结果：通用CAR-T细胞会首次生物体测试疗程发作/难治持续性T细胞会急持续性白血球会乳癌（r/r T-ALL）的实用持续性和。全会：开发计划当中的疗程技术-免疫疗程。原作者：称王岂料等简述：3013剧照：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利他汀在后半期输尿管突起细胞会胰脏症状当中的分析方法：一项随机的解禁字句II期测试（ORIENT-2）。全会：消化系统胰脏-食道输尿管胰脏、肝脏胰脏和食道胆道胰脏原作者：徐建明研究员等简述：4511剧照：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D专一持续性CAR-T细胞会对脾脏母细胞会瘤的根除持续性疗程全会：当中枢神经系统原作者：代红久、孙斌、杨东、徐晖、潘晶晶、魏佳、吴旭东简述：2522剧照。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复毛病症状当中的分析方法全会：开发计划当中的疗程学-免疫疗程原作者：沈琳研究员等简述：3021剧照。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程发作/难治持续性ACUTE白血球会乳癌/淋巴瘤的尚未有生物体诊疗测试全会: 开发计划持续性疗程学-免疫疗程原作者简介：张明志，最初兴镇等简述：3026剧照: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头应可用后半期实体瘤症状的Ib期数据分析全会：发展持续性疗程学--分子靶向口服和生命体学原作者：龚继芳，沈琳研究员等简述：3523剧照：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头紫杉醇和nedaplatin疗程风湿热或心肌梗死输尿管突起细胞会胰脏（ESCC）症状的II期数据分析。全会：消化系统胰脏-食道输尿管、肝脏和食道胆道胰脏的数据分析原作者：称王志最弱，刘玉红，称王德申，称王凤华，任超，谭琼 称王志最弱、刘玉红、称王德深、称王凤华、任超、谭琼简述：4522剧照：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全会：消化系统胰脏-食道输尿管胰脏、肝脏胰脏和食道胆管胰脏的二线疗程原作者：宋艳等简述：4524剧照：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体网状RNA分类器可用初始活检时检测高等级胰脏的尿液外体网状RNA分类器：一项多当中心地带的回顾持续性数据分析全会：泌尿生殖系统乳癌---胰脏、睾丸胰脏和胰脏原作者简介：Liaoyuan Li等简述：5522剧照。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 均匀分布后半期宫颈胰脏即刻化学治疗后的基本功能化学治疗全会: 妇科乳癌原作者简介： 刘珉珉等简述：6031剧照：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程心肌脾脏持续性胰脏的相关持续性：基于ALTER01031测试的数据分析。会话：躯干原作者：天津病房实是研究员简述：6526剧照。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小不一和年龄对安洛替尼疗程后症状结局的影响: ALTER01031的亚组数据分析全会：躯干原作者：天津病房实是研究员简述：6527剧照。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA数据分析预期I-IIIA期非小细胞会肺胰脏（NSCLC）症状术后发作: GASTO1035和GASTO1018的结果全会：肺胰脏-非小细胞会均匀分布-地区持续性/小细胞会/小细胞会/其他胸科乳癌原作者：Si-Yu Wang等简述：9023剧照：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞会肺胰脏（NSCLC）当中EGFR赖氨酸还原酶抑制剂的最初型细菌性机制全会:肺胰脏-非小细胞会心肌梗死肺胰脏原作者简介：吴昕，金玲玲，满宇，欧秋香，凯氏，薛武，杨少，范敏 吴昕、金玲玲、满宇、欧秋香、凯氏、薛武、杨绍、范敏简述：9528剧照：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1测试当中叶脑瘤总存活的替代站起全会：脑瘤/皮肤胰脏原作者：聂润聪，袁书最弱，刘元芳，陈英波，周志伟 聂润聪、袁书最弱、刘元芳、陈英波、周志伟简述：10030剧照：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程发作或心肌梗死原发持续性恶持续性骨症状的II期数据分析全会： 病变原作者：唐丽娜，牛晓辉，称王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、称汪直、蔡启庆、涂崇奇、范正福、杨瑶简述：11525剧照。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评论者安罗替尼在后半期病变症状多线疗程当中的实用持续性和。全会：病变原作者：姚伟涛，称王家最弱，王文，称王欣，杜最初辉，田志浩，牛晓颖 姚伟涛、称王家最弱、王文、称王鑫、杜鑫辉、田志超、牛晓英简述：11526剧照：414